Cerebral edema

Outlook Therapeutics Reports Financial Results for Third Quarter of Fiscal Year 2021 and Provides Corporate Update

Retrieved on: 
fredag, augusti 13, 2021
U.S. Securities and Exchange Commission, Hand, Retina, Calendar, Director, Diosynth, Growth, Sale, Safety, VEGF, Anti–vascular endothelial growth factor therapy, Eye, Industry, PHSA, DME, Therapy, FDA, Annual report, Appointment, Diabetic retinopathy, Public Health Service Act, Bleeding, CEO, Blood, Bevacizumab, COVID-19, Retinal, Board, BRVO, Risk, Physician, Mab, AMD, Terminology, BLA, Special Protection Area, GLOBE, Marketing, Security (finance), Patient, Nasdaq, BVCA, United States Public Health Service, Cerebral edema, Pharmaceutical industry, Medical imaging

The past quarter for Outlook Therapeutics has been truly transformative for the company.

Key Points: 
  • The past quarter for Outlook Therapeutics has been truly transformative for the company.
  • Most recently, Outlook Therapeutics reported positive topline data from its NORSE TWO pivotal Phase 3 clinical trial.
  • Outlook Therapeutics cash and cash equivalents on hand are sufficient to fund planned operations through December 2021.
  • Outlook Therapeutics expects to submit ONS-5010 ophthalmic bevacizumab to the U.S. FDA as a BLA under the PHSA 351(a) regulatory pathway.

Plus Therapeutics to Present Data from Two Studies Supporting the Treatment of Leptomeningeal Metastases with Rhenium-186 Nanoliposome

Retrieved on: 
onsdag, augusti 11, 2021
PSTV, 2021 Essex County Council election, IND, University of Texas at Austin, Index (publishing), Nasdaq, Therapy, Radiation, Cohort study, Safety, Neurology, Company, Patient, Diagnosis, Nanotechnology, U.S. Securities and Exchange Commission, Risk, Neurosurgery, Partnership, CNS, Conference, MFD, Part, MTD, Pakistan Society of Neuro-Oncology, LM, Clinical trial, Society, SNO, Cancer, COVID-19, Survival, Research, Associate, Central nervous system, Cerebral edema, Neoplasm, RNL, Perception, Intellectual property, FDA, EDT, GLOBE, University, Regulation, Plus, Drug development, Pharmaceutical industry, Medical imaging

The data will be presented at the Third Annual Conference on Brain Metastases hosted by the Society for Neuro-Oncology (SNO), being held virtually August 19-20, 2021.

Key Points: 
  • The data will be presented at the Third Annual Conference on Brain Metastases hosted by the Society for Neuro-Oncology (SNO), being held virtually August 19-20, 2021.
  • Thus far, the therapy has been well tolerated with one possible treatment-related serious adverse event, cerebral edema, that resolved after steroid treatment.
  • In addition, this abstract details a proposed two-part clinical trial for patients with leptomeningeal metastases (LM).
  • Plus Therapeutics (Nasdaq: PSTV) is a clinical-stage pharmaceutical company whose radiotherapeutic portfolio is concentrated on nanoliposome-encapsulated radionuclides for several cancer targets.

Diabetic Retinopathy Drug Pipeline Research Report 2021 - ResearchAndMarkets.com

Retrieved on: 
torsdag, augusti 5, 2021
General Health, Pharmaceutical, Health, Brolucizumab, Clinical trial, Discovery, Diabetic retinopathy, Cerebral edema, Novartis, Route, Administration, Therapy, Fragment crystallizable region, Patient, Growth, Route of administration, NAV, Vascular endothelial growth factor, News, III, II, Drug development, Pharmaceutical industry

The "Diabetic Retinopathy - Pipeline Insight, 2021" clinical trials has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Diabetic Retinopathy - Pipeline Insight, 2021" clinical trials has been added to ResearchAndMarkets.com's offering.
  • This Diabetic retinopathy - Pipeline Insight, 2021 provides comprehensive insights about 50+ companies and 50+ pipeline drugs in Diabetic retinopathy pipeline landscape.
  • This segment of the Diabetic retinopathy report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery.
  • Diabetic retinopathy pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.

Case Study Series Published in Journal of Neuroscience Nursing Demonstrates NeurOptics’ Pupillometry is Key Tool for Neurological Assessment

Retrieved on: 
tisdag, maj 11, 2021
Mental health, Nursing, Medical devices, Hospitals, Clinical trials, Cardiology, Practice Management, Biotechnology, Health, Optical, Neurological pupil index, Vision, Pupillometry, Pupilometer, Branches of biology, Neurology, Cerebral edema, Neuropsychological assessment

b'A new case study series published in the Journal of Neuroscience Nursing demonstrated that automated infrared pupillometry is an accurate tool that provides reliable data in patients with a poor baseline neurological examination after stroke.

Key Points: 
  • b'A new case study series published in the Journal of Neuroscience Nursing demonstrated that automated infrared pupillometry is an accurate tool that provides reliable data in patients with a poor baseline neurological examination after stroke.
  • The study examined the reliability and accuracy of automated pupillometry for neurological assessments.
  • Patients were monitored hourly using NeurOptics\xe2\x80\x99 infrared automated pupillometer, which calculates a Neurological Pupil index (NPi).
  • In each case, abnormal NPi values prompted emergent imaging that confirmed acute cerebral edema, resulting in a change in management and treatment plan.